These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36682464)

  • 1. Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Zhu Y; Li M; Liu N; Wu T; Han X; Zhao G; He Y
    Antiviral Res; 2023 Mar; 211():105541. PubMed ID: 36682464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Hu Y; Zhu Y; Yu Y; Liu N; Ju X; Ding Q; He Y
    Antiviral Res; 2023 Apr; 212():105571. PubMed ID: 36868315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif.
    Wu T; Zhu Y; Liu N; Hu Y; Chong H; He Y
    Front Microbiol; 2022; 13():1022006. PubMed ID: 36304946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
    Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
    mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
    Zhu Y; Dong X; Liu N; Wu T; Chong H; Lei X; Ren L; Wang J; He Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1819-1827. PubMed ID: 35786417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
    Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
    Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
    Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
    Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
    Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
    J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2.
    Sakib MMH; Nishat AA; Islam MT; Raihan Uddin MA; Iqbal MS; Bin Hossen FF; Ahmed MI; Bashir MS; Hossain T; Tohura US; Saif SI; Jui NR; Alam M; Islam MA; Hasan MM; Sufian MA; Ali MA; Islam R; Hossain MA; Halim MA
    Comput Biol Med; 2021 Sep; 136():104759. PubMed ID: 34403938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Miniprotein.
    Weißenborn L; Richel E; Hüseman H; Welzer J; Beck S; Schäfer S; Sticht H; Überla K; Eichler J
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
    Yu D; Zhu Y; Jiao T; Wu T; Xiao X; Qin B; Chong H; Lei X; Ren L; Cui S; Wang J; He Y
    Emerg Microbes Infect; 2021 Dec; 10(1):1227-1240. PubMed ID: 34057039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.